Warning! GuruFocus detected
1 Severe warning sign
with GKOS.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Current and historical daily PS Ratio for Glaukos Corp (
) from 2015 to May 14 2025. The price to sales ratio is calculated by taking the current stock price and dividing it by the trailing twelve-month sales per share. The data is updated every 20 minutes during market hours. The PS ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS ratio is a great valuation tool for evaluating cyclical businesses where the PE ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean. Glaukos stock (GKOS) PS ratio as of May 14 2025 is 12.46.
More Details
Glaukos Corp (GKOS) PS Ratio Chart
Glaukos Corp (GKOS) PS Ratio Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1226
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Glaukos PS Ratio Historical Data | |||
|---|---|---|---|
| Date | PS Ratio Data | Date | PS Ratio Data |
| 2025-05-14 | 12.5 | 2025-03-11 | 13.4 |
| 2025-05-13 | 12.4 | 2025-03-10 | 13.3 |
| 2025-05-12 | 12.7 | 2025-03-07 | 14.3 |
| 2025-05-09 | 12.1 | 2025-03-06 | 14.2 |
| 2025-05-08 | 12.2 | 2025-03-05 | 15.4 |
| 2025-05-07 | 11.9 | 2025-03-04 | 15.4 |
| 2025-05-06 | 11.7 | 2025-03-03 | 15.0 |
| 2025-05-05 | 11.7 | 2025-02-28 | 16.5 |
| 2025-05-02 | 11.8 | 2025-02-27 | 16.3 |
| 2025-05-01 | 11.2 | 2025-02-26 | 16.6 |
| 2025-04-30 | 12.7 | 2025-02-25 | 16.6 |
| 2025-04-29 | 12.6 | 2025-02-24 | 17.1 |
| 2025-04-28 | 12.6 | 2025-02-21 | 17.3 |
| 2025-04-25 | 13.0 | 2025-02-20 | 21.6 |
| 2025-04-24 | 12.8 | 2025-02-19 | 22.1 |
| 2025-04-23 | 12.5 | 2025-02-18 | 21.0 |
| 2025-04-22 | 12.1 | 2025-02-14 | 21.0 |
| 2025-04-21 | 11.9 | 2025-02-13 | 20.1 |
| 2025-04-17 | 12.2 | 2025-02-12 | 19.7 |
| 2025-04-16 | 11.9 | 2025-02-11 | 20.0 |
| 2025-04-15 | 12.7 | 2025-02-10 | 20.6 |
| 2025-04-14 | 12.5 | 2025-02-07 | 21.0 |
| 2025-04-11 | 12.1 | 2025-02-06 | 21.3 |
| 2025-04-10 | 12.1 | 2025-02-05 | 21.6 |
| 2025-04-09 | 12.6 | 2025-02-04 | 21.2 |
| 2025-04-08 | 11.1 | 2025-02-03 | 21.4 |
| 2025-04-07 | 11.6 | 2025-01-31 | 21.5 |
| 2025-04-04 | 11.3 | 2025-01-30 | 21.7 |
| 2025-04-03 | 11.7 | 2025-01-29 | 21.8 |
| 2025-04-02 | 13.5 | 2025-01-28 | 21.9 |
| 2025-04-01 | 13.1 | 2025-01-27 | 21.6 |
| 2025-03-31 | 13.3 | 2025-01-24 | 22.0 |
| 2025-03-28 | 13.7 | 2025-01-23 | 22.1 |
| 2025-03-27 | 14.2 | 2025-01-22 | 22.0 |
| 2025-03-26 | 14.2 | 2025-01-21 | 21.9 |
| 2025-03-25 | 14.7 | 2025-01-17 | 21.5 |
| 2025-03-24 | 14.8 | 2025-01-16 | 21.5 |
| 2025-03-21 | 14.1 | 2025-01-15 | 20.6 |
| 2025-03-20 | 13.8 | 2025-01-14 | 20.3 |
| 2025-03-19 | 13.9 | 2025-01-13 | 20.9 |
| 2025-03-18 | 13.8 | 2025-01-10 | 21.5 |
| 2025-03-17 | 14.2 | 2025-01-08 | 21.7 |
| 2025-03-14 | 14.0 | 2025-01-07 | 21.5 |
| 2025-03-13 | 13.3 | 2025-01-06 | 21.3 |
| 2025-03-12 | 14.2 | 2025-01-03 | 20.8 |
Glaukos Corp (GKOS) PS Ratio Comparison
| Company | Market Cap(Mil) | PS Ratio |
|---|
Business Description
Business Description
Glaukos Corp
NAICS : 339112
SIC : 3845
ISIN : US3773221029
Description
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers